F8 and hemophilia A: It was demonstrated in in vitro experiments using a number ofhybrid FVIII molecules with the deleted B domain 741–1648, which containedalternating fragments of porcine and human FVIII, that the replacement of the484–508 fragment of the A2 domain of human FVIII by a homologous fragment ofporcine FVIII and complete replacement of the human FVIII A3- and C2 domains bythe corresponding domains of porcine FVIII (variant HP32, Fig.8H) allow one to produce a FVIII molecule that is resistant to theinhibitor effect of most antibodies isolated from hemophilia A patients [184].